Ginkgo Biloba for Tinnitus: What the Clinical Evidence Actually Shows in 2026
Ginkgo biloba for tinnitus is the most-studied herbal intervention for ear ringing — and its clinical record is more complicated than most supplement retailers acknowledge. The 2013 Cochrane systematic review, the highest-quality synthesis of randomized controlled trials, found no reliable evidence that ginkgo outperforms placebo for tinnitus relief. The largest single trial enrolled over 1,100 patients. Yet several smaller trials using the standardized EGb 761 extract at higher doses have reported statistically significant improvements, particularly in patients whose tinnitus appears linked to impaired cochlear circulation. The honest clinical picture is one of mixed evidence, meaningful drug interactions, and a patient population question that most supplement marketing ignores entirely.
This review covers the full clinical evidence base — including the Cochrane consensus, the EGb 761 dose question, the mechanistic rationale, and the realistic answer to who might benefit and who probably won’t.
TL;DR
- The Cochrane review says no: The 2013 systematic review found insufficient evidence that ginkgo biloba is more effective than placebo for tinnitus.
- Largest RCT (1,121 patients): Drew & Davies 2001 — no significant difference between EGb 761 and placebo over 12 weeks.
- EGb 761 at 240 mg/day: The standardized extract at this dose has shown positive results in smaller trials; non-standardized ginkgo products are not equivalent to the research extract.
- Drug interactions are real: Ginkgo significantly increases bleeding risk with warfarin, aspirin, NSAIDs, and several other medications — not a casual supplement.
- Who may benefit: Tinnitus secondary to cerebrovascular insufficiency or poor cochlear microcirculation — a specific subgroup, not the general tinnitus population.
- For how ginkgo fits within the broader hearing supplement landscape, see our how tinnitus supplements work guide.
What Ginkgo Biloba Is — Botanical and Extract Overview
Ginkgo biloba is one of the oldest living tree species — a living fossil with a fossil record extending 200 million years. Its leaves contain a complex mixture of bioactive compounds, primarily flavone glycosides (including quercetin, kaempferol, and isorhamnetin glycosides) and terpene lactones (ginkgolides A, B, C, J, and bilobalide). Raw ginkgo leaf contains these compounds in variable concentrations; standardized extracts specify precise ratios.
EGb 761 — the extract used in the majority of ginkgo clinical research — is standardized to:
- 24% flavone glycosides (by weight)
- 6% terpene lactones (by weight)
This standardization matters clinically because the terpene lactones — particularly ginkgolide B — are responsible for the platelet-activating factor (PAF) antagonism that drives both the potential circulatory benefits and the anticoagulant drug interactions. Non-standardized ginkgo products may contain substantially different terpene lactone concentrations and cannot be assumed to replicate EGb 761’s pharmacological profile.
EGb 761 is sold under the brand name Tebonin in Germany (where it has pharmaceutical-grade regulatory status), Rökan in other European markets, and Tanakan in France. In the United States, ginkgo is sold as a dietary supplement without the pharmaceutical oversight applied to it in Europe.
Why Ginkgo Is Theoretically Relevant to Tinnitus
The mechanistic rationale for ginkgo in tinnitus has two primary pillars:
1. Cochlear Microcirculation
The inner ear is exquisitely sensitive to changes in blood supply. The cochlea — the spiral hearing organ — is perfused by the labyrinthine artery, a single end-arterial vessel with no meaningful collateral circulation. Any reduction in cochlear blood flow can cause auditory symptoms including tinnitus, sudden hearing loss, and vertigo.
Ginkgo biloba’s flavone glycosides act as antioxidants and vasodilators, while ginkgolide B inhibits PAF — a potent mediator of platelet aggregation and vasoconstriction. The proposed mechanism is that EGb 761 improves blood viscosity and microvascular flow to the cochlea, potentially reducing tinnitus in cases where poor cochlear perfusion is a contributing factor.
The theoretical link is strongest in:
- Age-related hearing and tinnitus (where cochlear vascular changes are common)
- Tinnitus in the context of vertigo or Menière’s-like symptoms
- Tinnitus associated with documented cerebrovascular insufficiency
2. Neuroprotection and Antioxidant Effects
Oxidative stress plays a role in cochlear hair cell damage — the irreversible injury that underlies both sensorineural hearing loss and the tinnitus that often accompanies it. Ginkgo’s flavone glycosides are free-radical scavengers that may reduce oxidative damage to cochlear neurons and hair cells.
The evidence for this neuroprotective mechanism is primarily animal-model data. Human trials haven’t been designed to isolate the antioxidant mechanism from the circulatory mechanism, making it difficult to attribute any clinical benefit to this pathway specifically. Understanding the full picture of how cochlear damage drives tinnitus is covered in our what causes tinnitus guide.
The Clinical Evidence: What the Trials Actually Show
The Cochrane Systematic Review (2013)
The most authoritative synthesis of ginkgo research in tinnitus is the Cochrane systematic review by Hilton, Zimmermann, and Hunt (Cochrane Database of Systematic Reviews, 2013, CD003852). Cochrane reviews are methodologically rigorous, pre-registered systematic reviews — the highest level of clinical evidence synthesis.
The 2013 review examined randomized controlled trials of ginkgo for tinnitus and concluded:
“There is no reliable evidence that ginkgo biloba is effective for tinnitus.”
Key findings from the review:
- The number of high-quality RCTs was small
- The largest trial (Drew & Davies 2001) found no significant benefit
- Several smaller positive trials had methodological weaknesses — including inadequate blinding and poorly defined outcome measures
- Heterogeneous patient populations across studies made meta-analysis unreliable
This is the current scientific consensus position, and it should be stated plainly before discussing any individual positive trials.
The Drew & Davies 2001 BMJ Trial (Largest RCT)
Drew S, Davies E. (BMJ, 2001, PMID 11232444) — conducted 1,121 patients with tinnitus in a randomized, double-blind, placebo-controlled trial of ginkgo biloba extract (preparation equivalent to EGb 761 at 150 mg/day) versus placebo for 12 weeks.
Results: No significant difference between ginkgo and placebo on any primary or secondary tinnitus outcome measure. The ginkgo group showed similar response rates to the placebo group across loudness, severity, and impact assessments.
This is the trial that fundamentally changed clinical expectations for ginkgo in tinnitus. Prior to this, smaller trials had created a modest evidence base for ginkgo efficacy; Drew & Davies — the largest RCT by far — did not support it.
Important caveat: the dose used (150 mg/day equivalent) was below the 240 mg/day used in some positive trials. Whether dose explains the null result is debated. The Cochrane reviewers did not find this argument convincing enough to change their overall conclusion.
Morgenstern & Biermann 2002 (Positive Trial)
Morgenstern C, Biermann E. (Phytomedicine, 2002, PMID 12244481) — 100 patients with tinnitus of vascular origin received EGb 761 at 240 mg/day versus placebo for 12 weeks in a randomized, double-blind trial. At 12 weeks, the EGb 761 group showed statistically significant improvement in tinnitus loudness and distress measures versus placebo.
Critical distinctions from the Drew & Davies trial:
- Higher dose: 240 mg/day versus 150 mg/day equivalent
- More specific population: patients with tinnitus of vascular origin rather than general tinnitus
- Smaller sample: 100 patients versus 1,121 — with correspondingly greater susceptibility to positive bias
This is the trial most frequently cited by ginkgo proponents. The tinnitus-of-vascular-origin selection criterion is clinically meaningful — if EGb 761’s mechanism works through cochlear microcirculation improvement, selecting patients whose tinnitus is plausibly caused by vascular factors makes biological sense. However, diagnosing “tinnitus of vascular origin” clinically is not straightforward.
Ernst & Stevinson 1999 Review
Ernst E, Stevinson C. (Clinical Otolaryngology, 1999, PMID 10356299) — an earlier systematic review of five ginkgo RCTs found “promising though not compelling” evidence for ginkgo in tinnitus. The review predated the much larger Drew & Davies trial and thus drew on smaller, methodologically weaker studies. It is primarily of historical interest — the post-2001 evidence base substantially revised the overall picture.
EGb 761 Dose: Does It Matter?
The dose question is unresolved but clinically relevant:
| Trial | Dose | Patient Population | Result |
|---|---|---|---|
| Drew & Davies 2001 | 150 mg/day EGb 761 equivalent | General tinnitus (n=1,121) | No benefit vs placebo |
| Morgenstern & Biermann 2002 | 240 mg/day EGb 761 | Tinnitus of vascular origin (n=100) | Significant improvement |
| Kleijnen & Knipschild 1992 | 160 mg/day | Mixed tinnitus | Mixed results |
The overlap between dose differences and population differences makes it impossible to attribute the divergent results to dose alone. The larger trial’s null result at 150 mg/day cannot be confidently redeemed by a smaller trial’s positive result at 240 mg/day when the populations also differ.
The NCCIH ginkgo overview notes that 240 mg/day divided across two to three doses is the typical research dose for circulatory and auditory indications. If you choose to trial EGb 761 for tinnitus — having consulted a healthcare provider and ruled out contraindications — 240 mg/day standardized extract is a more defensible choice than 120 mg/day, based on the more specific trial data.
Drug Interactions and Safety: The Underreported Concern
This section deserves more prominence than it receives in most ginkgo supplement discussions.
Anticoagulant and Antiplatelet Interactions
Ginkgolide B is a potent PAF antagonist — it inhibits platelet-activating factor, a key mediator of platelet aggregation. This creates additive bleeding risk when ginkgo is combined with:
- Warfarin (Coumadin): Clinically documented interaction — ginkgo can increase INR unpredictably
- Aspirin and NSAIDs: Additive antiplatelet effects
- Clopidogrel (Plavix): Synergistic antiplatelet mechanism
- Heparin and low-molecular-weight heparins: Additive anticoagulation
- Fish oil at high doses (>3g EPA+DHA): Additive platelet inhibition
For a population with tinnitus — who are often older adults who may be on aspirin or other cardiovascular medications — this is a real-world concern. The NCCIH advises against ginkgo use in people taking blood-thinning medications.
Other Interactions
- Antidepressants (SSRIs, MAOIs): Risk of serotonin syndrome with MAOIs; case reports of interaction with SSRIs
- Anticonvulsants: Ginkgo may lower seizure threshold, particularly at high doses
- Diabetes medications: Potential hypoglycemic effect requiring monitoring
- Cyclosporine: Ginkgo may reduce cyclosporine efficacy
Common Adverse Effects
In clinical trials at EGb 761 doses of 120–240 mg/day, reported adverse effects include:
- Headache (most common)
- GI disturbance (nausea, diarrhea)
- Dizziness
- Allergic skin reactions
Serious adverse events — particularly hemorrhagic events — are rare in clinical trials but have been reported in postmarket surveillance, predominantly in people combining ginkgo with anticoagulant medications.
Who Is Most Likely to Benefit From Ginkgo for Tinnitus
Based on the trial data and mechanistic rationale, the population with the most plausible chance of response includes:
Tinnitus with documented circulatory component:
- Tinnitus accompanied by dizziness or vertigo suggesting inner ear vascular involvement
- Tinnitus in the context of cerebrovascular insufficiency
- Tinnitus associated with age-related hearing decline where cochlear vascular changes are likely
Older adults with age-related hearing changes:
- Presbycusis (age-related sensorineural hearing loss) involves cochlear vascular changes that may make ginkgo’s microcirculatory mechanism more relevant
- The Morgenstern & Biermann positive trial specifically recruited patients whose tinnitus had a vascular etiology
For context on how ginkgo fits within the full landscape of tinnitus supplement ingredients — including magnesium, zinc, B vitamins, and vinpocetine — our how tinnitus supplements work guide covers the mechanistic categories and evidence quality for each.
Who Should Not Expect Benefits From Ginkgo
The evidence suggests ginkgo is least likely to help in:
Noise-induced tinnitus: Acoustic trauma causes irreversible cochlear hair cell damage through oxidative stress and mechanical injury — not through vascular insufficiency. Ginkgo’s microcirculatory mechanism has no clear relevance to established noise-induced damage.
Idiopathic tinnitus without vascular component: The Drew & Davies 2001 trial enrolled a general tinnitus population — likely dominated by idiopathic cases — and found no benefit. This is the most common clinical scenario and the one with the weakest evidence for ginkgo response.
Objective tinnitus: Pulsatile or other objective tinnitus (audible to an examiner) usually has structural causes — vascular anomalies, middle-ear conditions, palatal myoclonus — that herbal supplements cannot address.
Tinnitus from ototoxic medications: Drug-induced tinnitus (from aminoglycosides, cisplatin, loop diuretics, or high-dose salicylates) involves direct drug toxicity to cochlear hair cells. Removing or reducing the ototoxic agent is the relevant intervention.
Understanding what type of tinnitus you’re dealing with is essential before choosing any supplement. Our tinnitus vs hearing loss guide covers the diagnostic distinctions that matter for supplement selection.
How Ginkgo Compares to Other Tinnitus Supplement Ingredients
Ginkgo is not the only ingredient studied for tinnitus. Placing it in context helps calibrate realistic expectations:
Magnesium: Has meaningful evidence for noise-induced hearing protection and may support inner ear function. Several small RCTs support magnesium supplementation for acute acoustic trauma outcomes — a more specific mechanism than ginkgo’s broad circulatory action.
Zinc: Zinc deficiency is associated with tinnitus in some patient populations; repletion in zinc-deficient individuals has shown improvement in small trials. Like ginkgo, effect is population-specific — zinc does not help people with normal zinc status.
B vitamins (B12, folate): B12 deficiency is linked to inner ear dysfunction; repletion in deficient patients has shown modest tinnitus improvement. Again, population-specific.
Vinpocetine: Like ginkgo, works through cochlear microcirculation. Small positive trials exist, with a similar overall evidence picture to ginkgo.
None of these ingredients has overwhelming clinical evidence for tinnitus in the general population. The multi-ingredient formulas that address several pathways simultaneously — reviewed individually in our Audifort review, Zeneara review, and ZenCortex review — are the commercial approach to this multi-target problem.
What Product Labels Should Tell You (And Often Don’t)
If you’re evaluating ginkgo supplements for tinnitus support, here’s what the label needs to say to be worth considering:
Required:
- “EGb 761” or “standardized to 24% flavone glycosides and 6% terpene lactones” — this specifies the extract used in clinical research
- Serving size delivering 120–240 mg of the standardized extract per day
- Ginkgo biloba leaf (not seed — ginkgo seeds contain toxic ginkgotoxin)
Red flags:
- “Ginkgo biloba 500 mg” with no standardization statement — you don’t know what you’re getting
- “Proprietary blend” including ginkgo without disclosing per-ingredient doses
- Claims to “eliminate tinnitus” or “cure ringing ears” — these are unsupported and illegal structure/function claims
- No mention of drug interaction warnings for anticoagulant users
For a broader assessment of how commercial tinnitus supplements package these ingredients, our reviews of Quietum Plus, RhythmONE, Sonic Solace, and Echoxen examine how ginkgo and related ingredients are dosed in actual commercial formulas.
The Practical Decision Framework
Given the mixed evidence, here is the clearest way to think about ginkgo for your specific situation:
Try ginkgo only if:
- You have already addressed reversible tinnitus causes (earwax, medication, blood pressure)
- Your tinnitus has features suggesting a circulatory component (associated dizziness, age-related onset, variable intensity with posture or exercise)
- You are not taking anticoagulants, antiplatelet drugs, or the other interacting medications listed above
- You have discussed it with your prescriber
- You commit to 240 mg/day EGb 761 for at least 12 weeks before evaluating response
Do not try ginkgo if:
- You take warfarin, aspirin, clopidogrel, or other blood thinners
- Your tinnitus followed noise exposure (acoustic trauma)
- You have epilepsy or take anticonvulsants
- You have a known ginkgo or Ginkgoaceae allergy
This framework reflects the clinical trial subgroup data and the safety profile evidence — not a blanket endorsement or condemnation. Our about page covers how we apply evidence standards to supplement recommendations across this site.
Frequently Asked Questions
Does ginkgo biloba help tinnitus?
The current clinical consensus from the Cochrane systematic review is that ginkgo biloba is not reliably more effective than placebo for tinnitus. The largest single RCT (1,121 patients, Drew & Davies 2001) found no benefit. Smaller trials with specific populations — particularly those with circulation-related tinnitus — have shown positive results at 240 mg/day EGb 761. The honest answer is: probably not for most people, possibly for a specific subgroup.
What dose of ginkgo biloba is used for tinnitus?
EGb 761 at 120–240 mg/day in divided doses is the form and dose used in clinical trials. The 240 mg/day dose was used in the positive Morgenstern & Biermann 2002 trial. Non-standardized ginkgo leaf products at similar milligram doses are not equivalent to the standardized extract used in research.
How long does ginkgo take to work for tinnitus?
Clinical trials have assessed outcomes at 12 weeks. If ginkgo is going to produce any measurable change, allow a minimum of 12 weeks at 240 mg/day EGb 761 before drawing conclusions. If no improvement is detectable at 12 weeks, the probability of benefit with continued use is low.
Is ginkgo biloba safe for tinnitus?
For healthy adults not on interacting medications, short-term EGb 761 at research doses has an acceptable safety profile. The critical safety concern is drug interactions — particularly with warfarin, aspirin, clopidogrel, and NSAIDs — where ginkgo’s PAF antagonism creates additive bleeding risk. Always disclose ginkgo use to your prescriber.
What is EGb 761?
EGb 761 is the standardized ginkgo biloba leaf extract developed by Dr. Willmar Schwabe Pharmaceuticals, containing 24% flavone glycosides and 6% terpene lactones. It is the form used in the majority of published clinical trials and is available under brand names including Tebonin and Tanakan in Europe. It is not interchangeable with generic ginkgo leaf products.
Who is most likely to benefit from ginkgo for tinnitus?
The most plausible responders are people with tinnitus secondary to cerebrovascular insufficiency or poor cochlear microcirculation — particularly older adults with age-related hearing decline and associated vestibular symptoms. People with noise-induced tinnitus, idiopathic tinnitus, or objective tinnitus have the weakest rationale for ginkgo.
What does the Cochrane review say about ginkgo for tinnitus?
The 2013 Cochrane systematic review (Hilton, Zimmermann, Hunt) concluded there is “no reliable evidence” that ginkgo is more effective than placebo for tinnitus. The review found few high-quality RCTs, with the largest showing no benefit, and noted methodological weaknesses in smaller positive trials.
Can ginkgo biloba make tinnitus worse?
Ginkgo has not been shown to directly worsen tinnitus. However, its anticoagulant properties can create indirect risk — particularly in people on blood-thinning medications — and it has been associated with rare hemorrhagic events in combination with anticoagulants. These indirect risks can theoretically affect auditory symptoms.
The Bottom Line
Ginkgo biloba for tinnitus occupies an uncomfortable evidence position: it is the most-researched herbal for tinnitus, yet the best-quality evidence — the Cochrane systematic review and the largest RCT — does not support its use in the general tinnitus population. The smaller positive trials using EGb 761 at 240 mg/day in patients with circulation-related tinnitus provide a biological rationale for a specific subgroup, but this is not the same as recommending ginkgo broadly.
The drug interaction profile — particularly the anticoagulant effects — deserves more attention than it typically receives in supplement marketing. For older adults with tinnitus who are also managing cardiovascular conditions, ginkgo carries meaningful safety considerations that should factor into any decision.
If you are exploring ginkgo as part of a broader tinnitus management approach, understanding how it fits within the full landscape of evidence-based hearing support ingredients — and how commercial tinnitus supplements combine and dose these ingredients — is essential context. Our reviews of Audifort, Quietum Plus, Zeneara, and Echoxen each examine how ginkgo and related circulatory ingredients appear in commercial formulas targeting cochlear support.
For the broader mechanistic context on tinnitus supplements, our how tinnitus supplements work guide covers the pathway categories — circulatory support, antioxidant protection, neurotransmitter modulation — that inform multi-ingredient formula design.
You can read more about our research methodology and reviewer credentials on our about page. Our disclosure practices are detailed at our affiliate-disclosure page.
These statements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure, or prevent any disease. The information in this article is for educational purposes only and does not constitute medical advice. Consult a qualified healthcare professional before starting any supplement program or making changes to your treatment plan, especially if you have a diagnosed medical condition or take prescription medications.